Search
panobinostat (Farydak)
Indications:
- treatment of multiple myeloma in patients who had received at least 2 previous treatments, including bortezomib & a biological response modifier [1]
- for use in combination with bortezomib & dexamethasone [NGC, NICE]
Dosage:
Capsules: 10 mg, 15 mg, 20 mg
Adverse effects:
- most common
- diarrhea, fatigue, nausea, peripheral edema, anorexia, fever, vomiting, weakness
- most common laboratory abnormalities:
- hypophosphatemia, hypokalemia, hyponatremia, increased serum creatinine, thrombocytopenia, leukopenia, anemia
- hemorrhage: GI bleed, pulmonary hemorrhage
- hepatotoxicity
- boxed warning
- severe diarrhea
- severe & fatal cardiac events, arrhythmias & ECG changes
Mechanism of action:
- non-specific histone deacetylase inhibitor
General
heterocyclic compound, 2 rings
aromatic compound
amine
alkene; olefin
hydroxamic acid
histone decetylase inhibitor
antineoplastic agent (chemotherapeutic agent)
Database Correlations
PUBCHEM correlations
References
- Wikipedia: Panobinostat
http://en.wikipedia.org/wiki/Panobinostat
- FDA News Release. February 23, 2015
FDA approves Farydak for treatment of multiple myeloma
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm